10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin)

Recombinant Antibody
Catalog # APR10090

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P28908
Reactivity	Human
Clonality	ADC
Isotype	IgG1
Calculated MW	63747

Additional Information


Target/Specificity	TNFRSF8 / CD30
Endotoxin	
Conjugation	MMAE
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	TNFRSF8 (HGNC:11923)
Function	Receptor for TNFSF8/CD30L (PubMed: 8391931). May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa- B (PubMed:8999898).
Cellular Location	[Isoform 1]: Cell membrane; Single-pass type I membrane protein
Tissue Location	[Isoform 2]: Detected in alveolar macrophages (at protein level).


Images

Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.







The purity of Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) is 98.99%, determined by SEC-HPLC.



Immobilized human CD30 His at 2 ug/mL can bind Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin), EC50 is 0.006007 ug/mL.



MMAE is conjugated by sulfhydryl coupling,the DAR value of Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) antibody is 4.0.



Human TNFRSF8 / CD30 EGFP CHO Cell Line were stained with Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,The EC50 is 0.12 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.